TS-1 treatment for the carcinoma with an unknown primary site may be useful in patients who are not candidates for systemic platinum-based chemotherapy, because TTF1+ carcinoma patients are treated like non-small cell lung cancer patients. Here, TTF1 is linked to non-small cell lung carcinoma.